SurvivX is an early-stage biotech company developing a technology platform of potent innate immunity boosters to revive dysfunctional innate immune cells, which has therapeutic potential in multiple indications such as o.a. sepsis, trauma, major surgery, and as an innovative neoadjuvant (‘primer’ or ‘booster’) in cancer immuno-therapy.
We have a revolutionary new approach towards improving the outcome of diseases. We are developing a unique innate immune enhancer, which we call SUR-101, and is intended as a novel immune stimulating therapeutic and adjuvant.
How to become part of our journey
We are a young company, and we are full of ambitions. Here is how you can contribute: